# Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension

> **NCT01615198** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 588 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Olmesartan
- **DRUG:** Placebo
- **DRUG:** LCZ696

## Key facts

- **NCT ID:** NCT01615198
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 588 (ACTUAL)
- **Last updated:** 2015-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01615198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01615198, "Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01615198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*